GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » Total Long-Term Liabilities

Fusion Antibodies (LSE:FAB) Total Long-Term Liabilities : £0.03 Mil (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Fusion Antibodies's Total Long-Term Liabilities for the quarter that ended in Sep. 2024 was £0.03 Mil.


Fusion Antibodies Total Long-Term Liabilities Historical Data

The historical data trend for Fusion Antibodies's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies Total Long-Term Liabilities Chart

Fusion Antibodies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.09 0.02 0.06 0.04

Fusion Antibodies Semi-Annual Data
Mar15 Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.06 0.05 0.04 0.03

Fusion Antibodies Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.


Fusion Antibodies Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Fusion Antibodies Business Description

Traded in Other Exchanges
N/A
Address
1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL
Fusion Antibodies PLC offers various antibody engineering services for all therapeutic and diagnostic antibody development stages. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor 10-21-2022